Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
6.10
+0.15 (2.52%)
At close: Jul 3, 2025, 1:00 PM
6.16
+0.06 (0.97%)
After-hours: Jul 3, 2025, 4:51 PM EDT
Amicus Therapeutics Employees
Amicus Therapeutics had 499 employees as of December 31, 2024. The number of employees decreased by 18 or -3.48% compared to the previous year.
Employees
499
Change (1Y)
-18
Growth (1Y)
-3.48%
Revenue / Employee
$1,088,459
Profits / Employee
-$58,864
Market Cap
1.88B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FOLD News
- 8 days ago - Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan - GlobeNewsWire
- 13 days ago - U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts - GlobeNewsWire
- 17 days ago - The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy - GlobeNewsWire
- 20 days ago - In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid - GlobeNewsWire
- 21 days ago - In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime - GlobeNewsWire
- 21 days ago - Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma - Seeking Alpha
- 4 weeks ago - New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewsWire
- 4 weeks ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewsWire